Literature DB >> 10991862

Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells.

T V Achenbach1, E P Slater, H Brummerhop, T Bach, R Müller.   

Abstract

In this paper, we report that (+)-preussin, a pyrrolidinol alkaloid originally identified as an antifungal agent, has growth-inhibitory and cytotoxic effects on human cancer cells. Preussin was found to be a potent inhibitor of cyclin E kinase (CDK2-cyclin E) in vitro (50% inhibitory concentration; approximately 500 nM) and to inhibit cell cycle progression into S phase. In agreement with these findings, the level of the cyclin-dependent kinase inhibitor p27(KIP-1) is increased in response to preussin treatment while the expression of both cyclin A and the transcription factor E2F-1 is down-regulated. Preussin also induces programmed cell death (apoptosis), which requires caspase activation and involves the release of cytochrome c from mitochondria. This induction of apoptosis is not blocked by high levels of Bcl-2, which usually confers resistance to chemotherapeutic agents. Taken together, our data indicate that preussin could be a promising lead compound for the development of a new class of potent antitumor drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991862      PMCID: PMC90153          DOI: 10.1128/AAC.44.10.2794-2801.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Authors:  A M Senderowicz; D Headlee; S F Stinson; R M Lush; N Kalil; L Villalba; K Hill; S M Steinberg; W D Figg; A Tompkins; S G Arbuck; E A Sausville
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 2.  Traps to catch unwary oncogenes.

Authors:  A O Hueber; G I Evan
Journal:  Trends Genet       Date:  1998-09       Impact factor: 11.639

3.  Antitumoral activity of flavone L-86-8275.

Authors:  J Czech; D Hoffmann; R Naik; H Sedlacek
Journal:  Int J Oncol       Date:  1995-01       Impact factor: 5.650

4.  Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization.

Authors:  E Bossy-Wetzel; D D Newmeyer; D R Green
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

5.  Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

Authors:  K C Bible; S H Kaufmann
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

Review 6.  CDK inhibition and cancer therapy.

Authors:  M D Garrett; A Fattaey
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

7.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

Authors:  V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

8.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Authors:  D Wolf; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells.

Authors:  S Brüsselbach; D M Nettelbeck; H H Sedlacek; R Müller
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

10.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

View more
  8 in total

1.  A concise stereoselective synthesis of Preussin, 3-epi-Preussin, and analogues.

Authors:  Myra Beaudoin Bertrand; John P Wolfe
Journal:  Org Lett       Date:  2006-05-25       Impact factor: 6.005

2.  Palladium-Catalyzed Carboetherification and Carboamination Reactions of γ-Hydroxy- and γ-Aminoalkenes for the Synthesis of Tetrahydrofurans and Pyrrolidines.

Authors:  John P Wolfe
Journal:  European J Org Chem       Date:  2007-02

3.  Stereoselective Synthesis of Saturated Heterocycles via Pd-Catalyzed Alkene Carboetherification and Carboamination Reactions.

Authors:  John P Wolfe
Journal:  Synlett       Date:  2006-11-13       Impact factor: 2.454

4.  Diastereoselective pyrrolidine synthesis via copper promoted intramolecular aminooxygenation of alkenes: formal synthesis of (+)-monomorine.

Authors:  Monissa C Paderes; Sherry R Chemler
Journal:  Org Lett       Date:  2009-05-07       Impact factor: 6.005

5.  Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.

Authors:  Farhan Khan; Luisel J Ricks-Santi; Rabia Zafar; Yasmine Kanaan; Tammey Naab
Journal:  Ann Diagn Pathol       Date:  2018-04-05       Impact factor: 2.090

6.  Inhibition of Human Cervical Cancer Cell Growth by Ethanolic Extract of Boerhaavia diffusa Linn. (Punarnava) Root.

Authors:  Rakhi Srivastava; Daman Saluja; Bilikere S Dwarakanath; Madhu Chopra
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-02       Impact factor: 2.629

7.  The novel protective role of P27 in MLN4924-treated gastric cancer cells.

Authors:  Q Zhang; D Hou; Z Luo; P Chen; B Lv; L Wu; Y Ma; Y Chu; H Liu; F Liu; S Yu; J Zhang; D Yang; J Liu
Journal:  Cell Death Dis       Date:  2015-08-27       Impact factor: 8.469

8.  Cholesterol-Lowering Effects of Asperidine B, a Pyrrolidine Derivative from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178: A Potential Cholesterol Absorption Inhibitor.

Authors:  Atcharaporn Ontawong; Acharaporn Duangjai; Yaowapa Sukpondma; Kwanruthai Tadpetch; Chatchai Muanprasat; Vatcharin Rukachaisirikul; Jakkapong Inchai; Chutima S Vaddhanaphuti
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.